Pregnancy registry for women taking WAKIX (pitolisant)
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This registry collects information about pregnancy outcomes in women who took WAKIX (pitolisant) or a similar comparison medicine during pregnancy. It helps doctors understand the safety and effects of these medicines in pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently pregnant (any age).
- You agree to take part in the registry.
- Your pregnancy doctor can share your health and pregnancy data with the registry team.
- If you have narcolepsy: you took pitolisant or a comparator medicine at least once during pregnancy—or you were pregnant with narcolepsy but did not take these medicines at any time during pregnancy.
- If you do not have narcolepsy: you took pitolisant or a comparator medicine at least once during pregnancy.
- You must enroll before the pregnancy outcome has already happened (not a retrospective enrollment after delivery or loss).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that collects real-world information about pregnancy outcomes when relugolix-containing therapy is taken during pregnancy. It aims to better understand safety for both the parent during pregnancy and the child after birth.
This study looks at women who used a topical eczema cream called ruxolitinib (Opzelura) or steroid creams during pregnancy. The goal is to compare pregnancy outcomes and baby health up to one year after birth.
This registry study tracks the safety of Sunosi (solriamfetol) and other wakefulness medications taken during pregnancy. It aims to gather information to help doctors and pregnant women make informed treatment decisions.
This study compares the health of mothers and their babies in two groups: women with eczema who used ruxolitinib cream during pregnancy and those who did not. It aims to see if the cream is safe for both mother and child.
This study follows pregnant people who took tildrakizumab to understand pregnancy outcomes and safety. It also compares them with pregnant people with the same underlying disease who did not take tildrakizumab during this pregnancy.
This registry follows pregnant women with insomnia who used or did not use the sleep medication QUVIVIQ. It aims to track pregnancy and baby outcomes to understand safety.
Hear when a new Pregnancy Related trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.